SequelSEC

JUPITER NEUROSCIENCES, INC. JUNS

Pharmaceutical Preparations · CIK 0001679628 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$21.80K
Fiscal year ended 2025-12-31
Operating income
-$8.91M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

JUPITER NEUROSCIENCES, INC. (JUNS) reported revenue of $21.80K and net income of -$8.64M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from JUPITER NEUROSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

JUPITER NEUROSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$21.80K$0
Cost of revenue$4.23KUnavailable
Gross profit$17.56KUnavailable
Operating income-$8.91M-$3.09M
Net income-$8.64M-$2.44M
Research & development$2.09M$492.66K
Weighted-average diluted sharesshares 34.63Mshares 28.78M
Pretax incomeUnavailableUnavailable
Income tax expenseUnavailableUnavailable
Diluted EPS$-0.25$-0.08
Selling, general & administrative$6.84MUnavailable
General & administrative$6.84M$2.60M
Selling & marketingUnavailableUnavailable

Balance

JUPITER NEUROSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalentsUnavailableUnavailable
Total assets$5.56M$6.20M
Current assets$4.82M$4.65M
Total liabilities$7.40M$2.03M
Current liabilities$7.40M$2.01M
Total equity incl. NCI-$1.83M$4.17M
Temporary (mezzanine) equityUnavailableUnavailable
Inventory$159.79KUnavailable
Accounts receivable$2.64KUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payableUnavailableUnavailable

Cash flow

JUPITER NEUROSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$5.41M-$3.91M
Capital expendituresUnavailableUnavailable
Investing cash flowUnavailableUnavailable
Financing cash flow$5.43M$7.65M
Net change in cash$19.83K$3.74M
Stock-based compensation$2.42M$1.84M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

JUPITER NEUROSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flowUnavailableUnavailable
Gross margin80.6%Unavailable
Operating margin-40873.2%Unavailable
FCF marginUnavailableUnavailable
SBC / revenue11096.1%Unavailable
Current ratio0.65x2.31x
Revenue YoY growthUnavailableUnavailable
Net margin-39662.8%Unavailable
R&D / revenue9573.2%Unavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open JUNS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-04-01View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.